Streetbeat News

SNES

SenesTech, Inc.

https://www.senestech.com

Industry

Chemicals - Specialty

SenesTech, Inc. develops a technology for managing animal pest populations through fertility control. It offers ContraPest, a liquid bait that limits reproduction of male and female rats. The company was incorporated in 2004 and is headquartered in Phoenix, Arizona.

Open

2.30

Mkt cap

2.3M

Volume

5.6K

High

2.32

P/E Ratio

0.02

52-wk high

30.80

Low

2.19

Div yield

N/A

52-wk low

1.90

SenesTech has announced the deployment of its product, Evolve, in the U.S. Virgin Islands as part of an international effort to control invasive species in sensitive areas. This initiative is administered by the Wild Ecology Group.

Portfolio Pulse from Benzinga Newsdesk

June 26, 2024 | 1:16 pm

The article highlights the performance of 12 health care stocks during Thursday's after-market session. Notable gainers include Psyence Biomedical (PBM), Kintara Therapeutics (KTRA), and Clover Health Investments (CLOV). On the losing side, Kineta (KA) and Clene (CLNN) saw significant declines.

Portfolio Pulse from Benzinga Insights

June 20, 2024 | 8:31 pm

SenesTech has entered into an At The Market Offering Agreement with H.C. Wainwright, allowing it to sell shares of its common stock for up to $1,575,944.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 8:05 pm

The article highlights the performance of 12 healthcare stocks during Wednesday's after-market session. Sharps Technology (STSS) saw the highest gain with a 56.5% increase, while TransCode Therapeutics (RNAZ) experienced the largest decline, falling by 13.2%.

Portfolio Pulse from Benzinga Insights

May 22, 2024 | 8:31 pm

SenesTech has launched its Evolve fertility control solution for rats on Amazon, expanding its product availability and potentially increasing its market reach.

Portfolio Pulse from Benzinga Newsdesk

May 22, 2024 | 1:01 pm

HC Wainwright & Co. analyst Amit Dayal has reiterated a Buy rating on SenesTech (NASDAQ:SNES), maintaining a price target of $3.5.

Portfolio Pulse from Benzinga Newsdesk

May 14, 2024 | 4:12 pm

SenesTech shares are trading lower following the announcement of worse-than-expected Q1 financial results.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 4:50 pm

SenesTech reported Q1 2024 GAAP EPS of $(0.36), missing the $(0.34) estimate, and sales of $415K, below the $429K estimate. Despite these misses, the losses and sales figures represent significant improvements over the same period last year, with losses decreasing by 96.98% and sales increasing by 78.11%.

Portfolio Pulse from Benzinga Newsdesk

May 09, 2024 | 9:13 pm

In Thursday's pre-market session, several healthcare stocks showed significant movement. Processa Pharma led the gainers with a 31.2% increase, while Sunshine Biopharma experienced the largest drop among the losers, declining by 10.5%. The movements reflect varying market capitalizations and investor reactions to company-specific news or broader sector trends.

Portfolio Pulse from Benzinga Insights

April 25, 2024 | 12:06 pm

In Friday's intraday session, several healthcare stocks experienced significant movements. PaxMedica (PXMD) led the gainers with a 110.9% increase, while Motus GI Holdings (MOTS) saw the largest decline at 39%. Other notable movers include Q32 Bio (QTTB), Cyclacel Pharmaceuticals (CYCCP), and Rani Therapeutics Holdings (RANI) among the gainers, and Monogram Orthopaedics (MGRM) and BioSig Technologies (BSGM) among the losers.

Portfolio Pulse from Benzinga Insights

April 12, 2024 | 4:31 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.